Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Using GM-CSF as a Host Directed Therapeutic Against COVID-19 - a Phase 2 Investigator Initiated Trial

NCT04400929 is registered in ClinicalTrials.gov with Singapore General Hospital as lead sponsor.

NCT NCT04400929
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04400929 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Using GM-CSF as a Host Directed Therapeutic Against COVID-19 - a Phase 2 Investigator Initiated Trial
Lead sponsor
Singapore General Hospital
Phase
Phase 2
Overall status
Completed
Start date
June 2, 2020
Completion date
February 4, 2022
Enrollment
2 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ards, human, covid, sars-cov2